Bio-interventional Uveoscleral Outflow Enhancement Surgery for Primary Open-Angle Glaucoma: 2-Year Results of Cyclodialysis with Scleral Allograft Reinforcement
Ophthalmology Science · 2025-07 · 5 (4) · 100727
DOI: 10.1016/j.xops.2025.100727 ↗Kurz gefasst
Fachartikel in der Zeitschrift Ophthalmology Science, 2025-07. Verfasst von Ernesto Calvo und 4 weiteren Autor:innen. Beteiligte Einrichtung: Panama Eye Center, Panama City, Panama. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
To evaluate safety and efficacy of the scleral allograft-reinforced cyclodialysis through 24 months of follow-up.
Design
Interventional single-center case series.
Participants
Thirty-one eyes with primary open-angle glaucoma and visually significant cataracts underwent bio-interventional cyclodialysis surgery with scleral allograft reinforcement combined with phacoemulsification.
Intervention
Uveoscleral outflow enhancement surgery comprised of cyclodialysis with sequential bio-reinforcement with a scleral allograft combined with phacoemulsification. Main Outcome Measures: The primary outcome was the proportion of eyes achieving ≥20% intraocular pressure (IOP) reduction with same or fewer medications compared with baseline. Secondary outcomes included the mean change in medicated IOP and mean number of IOP-lowering medications compared with baseline. Adverse events were also recorded and evaluated throughout the study.
Results
The primary outcome was achieved in 74% of the eyes, and there was a mean IOP reduction of 34% compared with baseline. Baseline mean medicated IOP was 21.9 ± 4.92 mmHg on 1.22 ± 1.29 IOP-lowering medications. At 12 months postoperation, mean IOP was 12.62 ± 2.63 on 0.55 ± 0.52 glaucoma medications. The procedure was well tolerated, and there were no serious ocular adverse events.
Conclusions
Uveoscleral outflow enhancement can be successfully achieved at the time of cataract surgery through bio-interventional cyclodialysis and scleral allograft reinforcement to lower IOP in patients with primary open-angle glaucoma. Financial Disclosures: The author(s) have no proprietary or commercial interest in any materials discussed in this article.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Panama Eye Center, Panama City, Panama.
- John A. Moran Eye Center, University of Utah, Salt Lake City.
- Clinica de Olhos De Francesco, Fortaleza, Brazil.
- Hospital de Olhos Leiria de Andrade, Fortaleza, Brazil.
- Tyson Eye, Cape Coral, Florida.
- Shileye Eye Institute, University of California San Diego, San Diego.
Zitieren
APA
Calvo, E., De Francesco, T., Vera, L., Tyson, F., & Weinreb, R. N. (2025). Bio-interventional Uveoscleral Outflow Enhancement Surgery for Primary Open-Angle Glaucoma: 2-Year Results of Cyclodialysis with Scleral Allograft Reinforcement. Ophthalmology Science, 5(4), 100727. https://doi.org/10.1016/j.xops.2025.100727
Vancouver
Calvo E, De Francesco T, Vera L, Tyson F, Weinreb RN. Bio-interventional Uveoscleral Outflow Enhancement Surgery for Primary Open-Angle Glaucoma: 2-Year Results of Cyclodialysis with Scleral Allograft Reinforcement. Ophthalmology Science. 2025;5(4):100727. doi:10.1016/j.xops.2025.100727
BibTeX
@article{Calvo2025,
author = {Calvo, Ernesto and De Francesco, Ticiana and Vera, Lautaro and Tyson, Farrell and Weinreb, Robert N},
title = {Bio-interventional Uveoscleral Outflow Enhancement Surgery for Primary Open-Angle Glaucoma: 2-Year Results of Cyclodialysis with Scleral Allograft Reinforcement},
journal = {Ophthalmology Science},
year = {2025},
volume = {5},
number = {4},
pages = {100727},
doi = {10.1016/j.xops.2025.100727}
}
EUVIMED